NVO - UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity | Benzinga
Pharmaceutical giant Eli Lilly And Co (NYSE:LLY) is set to launch its highly-anticipated obesity drug, Mounjaro (tirzepatide), in Britain this week, making the U.K. the fourth European country to introduce the famed medication.
The drug, also approved for diabetes treatment, is expected to address the pressing issue of obesity, with nearly one in three adults in Britain classified as obese, the highest rate in Europe.
Superdrug announced Wednesday that eligible private patients could obtain Mounjaro prescriptions through its Online Doctor service starting Thursday.
Related Content: Eli Lilly’s Weight Loss Drug Tirzepatide Is Expanding Market Share, Analyst Outlines What Lies Ahead.
Despite this, the retail chain prioritized National Health Service (NHS) patients, considering the anticipated high demand, drawing parallels with the popularity of Novo Nordisk A/S’s (NYSE:NVO) rival weight-loss drug, Wegovy, introduced in the UK last year.
Britain’s Simple Online Pharmacy, another key player in the pharmacy landscape, reported the commencement of Mounjaro prescriptions on Tuesday.
Citing a spokesperson from Simple, Reuters highlighted the ...